News
ABUS
1.875
-0.27%
-0.005
Weekly Report: what happened at ABUS last week (0925-0929)?
Weekly Report · 2d ago
Weekly Report: what happened at ABUS last week (0918-0922)?
Weekly Report · 09/25 09:17
Weekly Report: what happened at ABUS last week (0911-0915)?
Weekly Report · 09/18 09:16
HC Wainwright & Co. Reiterates Arbutus Biopharma (ABUS) Buy Recommendation
NASDAQ · 09/13 04:15
Robert W. Baird Sticks to Its Hold Rating for Arbutus Biopharma (ABUS)
TipRanks · 09/12 14:45
Analysts Conflicted on These Healthcare Names: Roche Holding AG (OtherRHHVF) and Arbutus Biopharma (ABUS)
TipRanks · 09/12 11:00
HC Wainwright & Co. Reiterates Buy on Arbutus Biopharma, Maintains $6 Price Target
Benzinga · 09/12 10:27
H.C. Wainwright Keeps Their Buy Rating on Arbutus Biopharma (ABUS)
TipRanks · 09/12 10:15
Chardan Capital Remains a Buy on Arbutus Biopharma (ABUS)
TipRanks · 09/12 02:25
Arbutus ends development of COVID, hepatitis b candidates
Seeking Alpha · 09/11 21:32
Arbutus Biopharm: Current report
Press release · 09/11 21:18
Arbutus Biopharm: Statement of acquisition of beneficial ownership by individuals
Press release · 09/11 21:18
Weekly Report: what happened at ABUS last week (0904-0908)?
Weekly Report · 09/11 09:16
Weekly Report: what happened at ABUS last week (0828-0901)?
Weekly Report · 09/04 11:11
Pfizer, Moderna And COVID Vaccine Patents: Implications Of Legal Cases
Seeking Alpha · 08/30 20:04
Weekly Report: what happened at ABUS last week (0821-0825)?
Weekly Report · 08/28 09:17
Weekly Report: what happened at ABUS last week (0814-0818)?
Weekly Report · 08/21 11:06
Robert W. Baird Remains a Hold on Arbutus Biopharma (ABUS)
TipRanks · 08/08 09:15
H.C. Wainwright Sticks to Their Buy Rating for Arbutus Biopharma (ABUS)
TipRanks · 08/04 10:35
More
Webull provides a variety of real-time ABUS stock news. You can receive the latest news about Arbutus Biopharm through multiple platforms. This information may help you make smarter investment decisions.
About ABUS
Arbutus Biopharma Corporation is a clinical-stage, biopharmaceutical company. The Company is focused on virology capabilities to develop therapeutics that target specific viral diseases. The Company’s focus areas include Hepatitis B virus (HBV), SARS-CoV-2 and other coronaviruses. In HBV, the Company is developing a ribonucleic acid interference (RNAi) therapeutic, an oral capsid inhibitor, an oral programmed death-ligand-1 (PD-L1) inhibitor, and an oral RNA destabilizer that it intends to combine to provide a functional cure for patients with chronic HBV infection (cHBV) by suppressing viral replication, reducing surface antigen and reawakening the immune system. Its lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening and is being evaluated in multiple Phase II clinical trials. The Company is also having an ongoing drug discovery and development program directed at identifying orally active agents for treating coronaviruses, including SARS-CoV-2.